Canada markets closed

NextCure, Inc. (NXTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4000-0.0100 (-0.71%)
At close: 04:00PM EST
1.4000 0.00 (0.00%)
After hours: 04:02PM EST

NextCure, Inc.

9000 Virginia Manor Road
Suite 200
Beltsville, MD 20705
United States
240 399 4900
https://www.nextcure.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees87

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael S. Richman MSBACo-Founder, CEO, Pres & Director726.42kN/A1961
Dr. Solomon Langermann Ph.D.Chief Scientific Officer527.98kN/A1960
Dr. Han Myint FACP, M.D.Chief Medical Officer611.98kN/A1953
Dr. Lieping Chen M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/A1958
Mr. Steven P. Cobourn CPA, CPAChief Financial OfficerN/AN/A1963
Dr. Timothy Mayer Ph.D.Chief Operating OfficerN/AN/A1965
Mr. Sourav Kundu Ph.D.Sr. VP of Devel. & ManufacturingN/AN/A1960
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Corporate Governance

NextCure, Inc.’s ISS Governance QualityScore as of December 1, 2022 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.